Ultragenyx Pharmaceutical Inc. (RARE)
- Previous Close
41.22 - Open
41.54 - Bid 40.76 x 100
- Ask 40.89 x 100
- Day's Range
40.26 - 41.56 - 52 Week Range
31.52 - 54.98 - Volume
170,999 - Avg. Volume
737,346 - Market Cap (intraday)
3.388B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-7.95 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
88.85
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
www.ultragenyx.comRecent News: RARE
Performance Overview: RARE
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RARE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RARE
Valuation Measures
Market Cap
3.42B
Enterprise Value
3.05B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.17
Price/Book (mrq)
24.41
Enterprise Value/Revenue
6.90
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-138.58%
Return on Assets (ttm)
-26.97%
Return on Equity (ttm)
-340.05%
Revenue (ttm)
442.59M
Net Income Avi to Common (ttm)
-613.35M
Diluted EPS (ttm)
-7.95
Balance Sheet and Cash Flow
Total Cash (mrq)
412.08M
Total Debt/Equity (mrq)
664.59%
Levered Free Cash Flow (ttm)
-329.48M
Research Analysis: RARE
Company Insights: RARE
RARE does not have Company Insights